Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Brivanib alaninate

Generic Name: Brivanib alaninate

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄FN_₅O_₄

CAS Number: 649735-63-7

Unique Ingredient Identifier: U2Y5OFN795

Overview

Brivanib alaninate has been investigated for the treatment of Colorectal Cancer.

Background

Brivanib alaninate has been investigated for the treatment of Colorectal Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2

Completed

Posted: 2010/12/28

Sponsor:Gynecologic Oncology...

ID:NCT01267253

Brivanib Metastatic Renal Cell Carcinoma

Phase 2

Terminated

Posted: 2010/12/03

Sponsor:Abramson Cancer Cent...

ID:NCT01253668

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2

Completed

Posted: 2009/04/27

Sponsor:Gynecologic Oncology...

ID:NCT00888173

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Phase 1

Completed

Posted: 2008/11/26

Sponsor:Bristol-Myers Squibb

ID:NCT00798252

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Phase 3

Completed

Posted: 2008/03/21

Sponsor:NCIC Clinical Trials...

ID:NCT00640471

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy